Features of treatment, hospitalization and working ability of newly diagnosed patients with pulmonary arterial hypertension before and after diagnosis verification

Objective. The aim of the study is to examine treatment patterns, hospitalizations, work disability and describe demographic and clinical characteristics of newly diagnosed patients with pulmonary arterial hypertension (PAH) before and after diagnosis verification in real clinical practice in Russia. Design and methods. Longitudinal prospective observational study with a retrospective part was conducted. Adult patients were included after PAH verification based on right heart catheterization. The data was received via patients interviewing and medical documentation analysis at enrollment and every 3 months. The retrospective design was used to collect information before enrollment. Results. Thirty-three patients with newly diagnosed PAH were enrolled in the study. Most patients had II (45,5 %) or III (36,4 %) WHO functional class. During follow-up period 2 patients died because of PAH complications, 1 patient died due to COVID-19 complications, and 1 patient was lost for follow-up. Before PAH verification 12,1 % of all patients did not work due to PAH symptoms while after verification of the diagnosis this proportion doubled. Diuretics and mineralocorticoid-receptor antagonists were the most frequently used drugs before PAH diagnosis confirmation, 9 % of patients took sildenafil. Most patients (64 %) received monotherapy as initial PAH-specific treatment, in 34 % of all patients treatment was escalated within 12 months after PAH verification. The number of hospitalizations significantly decreased after PAH verification and specific therapy prescription (р < 0,05). Conclusions. This study demonstrated a decrease in the number of hospitalizations after PAH verification, which may confirm the effectiveness of various regimens of PAH-specific therapy in real clinical practice in Russia. In addition, the study identified a number of problems associated with PAH (predominance of initial monotherapy, low vaccination coverage, problems with drug provision, etc.) The solution of these problems may improve the outcomes.

1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al.; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731. doi:10.1093/eurheartj/ehac237

2. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1): 2045894020 977300. doi:10.1177/2045894020977300

3. State Register of Pharmaceutical Products. Accessed October 11, 2023. Available at: https://grls.rosminzdrav.ru/Default.aspx. In Russian

4. Vachiéry JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev. 2012;21(126):313–320. doi:10.1183/09059180.00005412

5. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216–223. doi:10.7326/0003-4819-107-2-216

6. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030. doi:10.1164/rccm.200510-1668OC

7. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010; 137(2):376–387. doi:10.1378/chest.09-1140

8. Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study. Pulm Circ. 2013;3(1):89–94. doi:10.4103/2045-8932.109919

9. Jansa P, Jarkovsky J, Al-Hiti H, Popelova J, Ambroz D, Zatocil T et al. Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry. BMC Pulm Med. 2014;14:45. doi:10.1186/1471-2466-14-45

10. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186(8):790–796. doi:10.1164/rccm.201203-0383OC

11. McGoon MD, Miller DP. REVEAL a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012; 21(123):8–18. doi:10.1183/09059180.00008211

12. Chazova IE, Arkhipova OA, Martynyuk TV. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry. Therapeutic Archive. 2019;91(1):24–23. doi:10.26442/00403660.2019.01.00002. In Russian.

13. Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017

14. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M et al. Prognostic value of follow-up hemodynamic variables after initial management in pulmonary arterial hypertension. Circulation. 2018;137(7):693–704. doi:10.1161/CIRCULATIONAHA.117.029254

15. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–788. doi:10.1016/s0735-1097(02)02012-0

16. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–172. doi:10.1161/CIRCULATIONAHA.109.898122

17. Hoeper MM, Pausch C, Grünig E, Staehler G, Huscher D, Pittrow D et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022;59(6):2102024. doi:10.1183/13993003.02024-2021

18. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al.; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. doi:10.1093/eurheartj/ehv317

19. Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV et al.; AMBITION Investigators. Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–844. doi:10.1056/NEJMoa1413687

20. Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ et al. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. Lancet Respir Med. 2016;4(11):894–901. doi:10.1016/S2213-2600(16)30307-1

21. Zakiev VD, Martynyuk TV, Vedernikov AA, Petrenko DA, Korkach-Romanov SV. Socio-economic burden of newly diagnosed pulmonary arterial hypertension and early specific treatment initiation impact on the costs in real clinical practice in Russia. Medical Technologies. Assessment and Choice. 2023;(1):99–113. doi:10.17116/medtech20234501199. In Russian.

22. Galkin SS, Bobylev SN, Burlakova EA, Vagan IS, Vasiliev IV, Volkov IN et al. Russian Statistical Yearbook 2022: Stat.book/Rosstat. R76 М. 2022. 691 p. In Russian.

23. Decree of the Government of the Russian Federation No. 403 of April 26, 2012 “On the procedure for maintaining the Federal register of persons suffering from life-threatening and chronic progressive rare (orphan) diseases leading to a reduction in the life expectancy of citizens or their disability, and its regional segment”. Accessed October 11, 2023. In Russian. Available at: https://base.garant.ru/70168888

24. Helgeson SA, Menon D, Helmi H, Vadlamudi C, Moss JE, Zeiger TK et al. Psychosocial and financial burden of therapy in USA patients with pulmonary arterial hypertension. Diseases. 2020;8(2):22. doi:10.3390/diseases8020022

25. Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3(1):1–8. doi:10.1016/j.jchf.2014.07.013

26. Yang X, Sanders KN, Mardekian J, Mychaskiw MA, Thomas J 3rd. Associations between sildenafil use and changes in days of hospitalization in a population with pulmonary arterial hypertension associated with connective tissue disease. Clin Ther. 2015;37(5):1055–1063. doi:10.1016/j.clinthera.2015.02.025

27. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N et al.; GRIPHON Investigators. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533. doi:10.1056/NEJMoa1503184

28. Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM et al.; AMBITION Study Group. Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension related hospitalization in the AMBITION trial. J Heart Lung Transplant. 2019;38(2):194–202. doi:10.1016/j.healun.2018.11.006

29. Fuge J, Park DH, von Lengerke T, Richter MJ, Gall H, Ghofrani HA et al. Impact of pulmonary arterial hypertension on employment, work productivity, and quality of life — results of a cross-sectional multi-center study. Front Psychiatry. 2022;12:781532. doi:10.3389/fpsyt.2021.781532